Final program - Changing Views in Cancer

Friday, May 27, 2016

Session I:

Chair: Soyoung Lee

09.15 – 09.30h Welcome/ Introduction

09.30 – 10.00h Juliet Williams: Human Clinical Trial in mice: Modeling interpatient response heterogeneity in PDXs.

10.00 – 10.30h Funda Meric-Berstam: Implementing Genomically- informed therapy.

10.30 – 10.45h Björn Gohlke: A resource for personalized tumor therapy. (Abstract talk)

10.45 – 11.15h Coffee break

Session II:

Chair: Gary Nolan

11.15 – 11.45h Daniel Cahill: IDH mutation and metabolism in glioma.

11.45 – 12.15h Nikolaus Rajewsky: Regulatory RNAs.

12.15 – 12.30h Albanderi Alfraidi: The roles of Fra-2 in lung adenocarcinoma progression. (Abstract talk)

12.30 – 14.15h Lunch/ Postersession

Session III:

Chair: Clemens Schmitt

14.15 – 14.45h Klaus Rajewsky: Cellular competition and fitness in lymphomagenesis.

14.45 – 15.15h Marco Gerlinger: Cancer heterogeneity and evolution: the ultimate challenge for precision cancer medicine.

15.15 – 15.45h Christian Steidl: Molecular outcome predictors in classical Hodgkin lymphoma.

15.45 – 16.15h Coffee break


Session IV:

Chair: Armin Gerbitz

16.15 – 16.45h Holger Gerhardt: Morphogenetic principles and functional implications of vascular malformation during tumour progression.

16.45 – 17.00h Carolin Barth: Role of ARHGAP39 in guided cell migration. (Abstract talk)

17.00 – 17.30h Ingolf Sack: In vivo biomechanical properties of tumors.

17.30 – 18.00h Jan Laufer: Anatomical and molecular photoacoustic imaging of tumours in vivo.


Saturday, May 28, 2016

Session V:

Chair: Reinhold Schäfer

09.15 – 09.45h Anas Younes: Novel mechanism-based immune therapy strategies in lymphoma.

09.45 – 10.15h Ryan M. Young: Novel mechanisms of pathogenic signaling in lymphoma.

10.15 – 10.30h Harikrishnan Radhakrishnan: MACC1 knockdown sensitizes colorectal cancer cells to FasL/FasR mediated apoptosis through modulation of STAT - Mcl-1 signaling axis (Abstract talk)

10.30 – 11.00h Clemens Schmitt: Conceptually novel therapies in lymphoma.

11.00 – 11.30h Coffee break 

Session VI:

Chair: Christian Reinhardt

11.30 – 12.00h Gary Nolan: A System-Based, Single Cell Structure for Cancer & Immunity.

12.00 – 12.30h Santiago Zelenay: Reducing prostaglandin E2 production to raise cancer immunogenicity.

12.30 – 12.45h Michele Mishto: Proteasome-generated spliced epitopes: the future targets for immunotherapy? (Abstract talk)

12.45 – 13.45h Lunch/ Postersession 

Session VII:

Chair: Claus Scheidereit

13.45 – 14.15h Jorge Pacheco: Eradication of cancer cells.

14.15 – 14.45h Christian Reinhardt: Systematic profiling of synergistic drug interactions to develop genotype-mapped cancer therapies.

14.45 – 15.00h Jayeta Saxena: Acquired resistance to the MEK1/2 inhibitor Selumetinib in BRAF mutant colorectal cancer cell lines is reversible upon drug withdrawal (Abstract talk)

15.00 – 15.30h Final remarks